Animal models for HIV/AIDS research
T Hatziioannou, DT Evans - Nature Reviews Microbiology, 2012 - nature.com
The AIDS pandemic continues to present us with unique scientific and public health
challenges. Although the development of effective antiretroviral therapy has been a major …
challenges. Although the development of effective antiretroviral therapy has been a major …
Host restriction factors in retroviral infection: promises in virus-host interaction
YH Zheng, KT Jeang, K Tokunaga - Retrovirology, 2012 - Springer
Retroviruses have an intricate life cycle. There is much to be learned from studying retrovirus-
host interactions. Among retroviruses, the primate lentiviruses have one of the more complex …
host interactions. Among retroviruses, the primate lentiviruses have one of the more complex …
Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition
A recombinant vaccine containing Aventis Pasteur's canarypox vector (ALVAC)–HIV and
gp120 alum decreased the risk of HIV acquisition in the RV144 vaccine trial. The substitution …
gp120 alum decreased the risk of HIV acquisition in the RV144 vaccine trial. The substitution …
[HTML][HTML] Vaccine-induced protection from homologous tier 2 SHIV challenge in nonhuman primates depends on serum-neutralizing antibody titers
MG Pauthner, JP Nkolola, C Havenar-Daughton… - Immunity, 2019 - cell.com
Passive administration of HIV neutralizing antibodies (nAbs) can protect macaques from
hard-to-neutralize (tier 2) chimeric simian-human immunodeficiency virus (SHIV) challenge …
hard-to-neutralize (tier 2) chimeric simian-human immunodeficiency virus (SHIV) challenge …
Antibodies with High Avidity to the gp120 Envelope Protein in Protection from Simian Immunodeficiency Virus SIVmac251 Acquisition in an Immunization Regimen …
The recombinant canarypox vector, ALVAC-HIV, together with human immunodeficiency
virus (HIV) gp120 envelope glycoprotein, has protected 31.2% of Thai individuals from HIV …
virus (HIV) gp120 envelope glycoprotein, has protected 31.2% of Thai individuals from HIV …
Nonhuman primate models for HIV/AIDS vaccine development
The development of HIV vaccines has been hampered by the lack of an animal model that
can accurately predict vaccine efficacy. Chimpanzees can be infected with HIV‐1 but are not …
can accurately predict vaccine efficacy. Chimpanzees can be infected with HIV‐1 but are not …
Molecularly tagged simian immunodeficiency virus SIVmac239 synthetic swarm for tracking independent infection events
GQ Del Prete, H Park, CM Fennessey, C Reid… - Journal of …, 2014 - Am Soc Microbiol
Following mucosal human immunodeficiency virus type 1 transmission, systemic infection is
established by one or only a few viral variants. Modeling single-variant, mucosal …
established by one or only a few viral variants. Modeling single-variant, mucosal …
Protection Afforded by an HIV Vaccine Candidate in Macaques Depends on the Dose of SIVmac251 at Challenge Exposure
We used the simian immunodeficiency virus mac251 (SIVmac251) macaque model to study
the effect of the dose of mucosal exposure on vaccine efficacy. We immunized macaques …
the effect of the dose of mucosal exposure on vaccine efficacy. We immunized macaques …
Pathogenicity and Mucosal Transmissibility of the R5-Tropic Simian/Human Immunodeficiency Virus SHIVAD8 in Rhesus Macaques: Implications for Use in Vaccine …
R Gautam, Y Nishimura, WR Lee, O Donau… - Journal of …, 2012 - Am Soc Microbiol
There is an urgent need to develop new pathogenic R5 simian/human immunodeficiency
viruses (SHIVs) for the evaluation of candidate anti-HIV vaccines in nonhuman primates …
viruses (SHIVs) for the evaluation of candidate anti-HIV vaccines in nonhuman primates …
Cutting edge: novel vaccination modality provides significant protection against mucosal infection by highly pathogenic simian immunodeficiency virus
Vaccine-induced protection against infection by HIV or highly pathogenic and virulent SIV
strains has been limited. In a proof-of-concept study, we show that a novel vaccine approach …
strains has been limited. In a proof-of-concept study, we show that a novel vaccine approach …